Biopix-T

What Biopix-T does

Biopix-T is a privately held Greek company, founded in 2019 and headquartered in Heraklion, Crete, that develops portable molecular diagnostic devices together with companion software for DNA/RNA testing. The product targets the decentralized, point-of-care segment of the in vitro diagnostics market, where compact hardware combined with assay and analysis software is intended to enable molecular testing outside centralized laboratories. The company is in an early stage, with 11–50 employees and a leadership team that combines hardware/product development (Alexandris Pantazis), scientific expertise (Electra Gizeli), software engineering (Nikolaos Fikas), and commercial and finance functions (CEO George Papadakis; CFO Konstantinos Chatzakis; Head of Commercial & Investor Relations Sergios Katsaros).

The company's only confirmed capital event is a $1.71 million funding round closed on 2020-09-09, led by Metavallon VC with participation from Eleven Ventures — both regional, early-stage investors. No subsequent funding rounds, partnerships, customer wins, product launches, or regulatory milestones are disclosed in the available source material, and the company's own website currently renders only a verification/loading screen rather than substantive product, pricing, or commercial information.

The business model is therefore not directly observable from the data. Reasonable inference is that Biopix-T follows a deep-tech medtech path: instrument + consumable/assay sales (or licensing) to clinical, research, or field-testing customers, with long regulatory and sales cycles typical of hardware molecular diagnostics. Pricing models, distribution channels, customer segmentation, and revenue mechanics cannot be confirmed from the source material and remain material data gaps for any prospective investor.

Name

Biopix-T

Website

https://biopix-t.com

Company type

Private

Founded year

2019

Headcount range

11–50 employees

Short description

Biopix-T develops portable molecular diagnostic devices and companion software for DNA/RNA testing, targeting decentralized point-of-care and field-testing use cases. Founded in 2019 in Heraklion, Greece, the company is an early-stage private deep-tech medtech with limited public disclosure.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro industry

PRIMARYHLAAALAL

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHDAHALAK

Biosensors & Lab-on-Chip (BioMEMS)

Hardware, Technology & Telecom/Semiconductors & Electronic Components/Sensors, MEMS & Optoelectronics

Keywords

• Molecular diagnostics
• DNA RNA testing
• Portable diagnostic devices
• Point-of-care diagnostics
• Nucleic acid detection

Headquarters

HQ city

Heraklion

HQ country

Greece

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Core offering

Biopix-T develops portable molecular diagnostic devices and accompanying software for DNA/RNA testing. The company combines miniaturized hardware instrumentation with proprietary software to enable molecular (nucleic acid) testing outside of centralized laboratory infrastructure. The offering is aimed at organizations performing molecular biology and diagnostic testing workflows.

Differentiator

Problem solved

Functional benefit

Products and services

• Portable molecular diagnostic devices

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Cepheid (Danaher): Cepheid's GeneXpert system is the reference point for portable, cartridge-based molecular DNA/RNA testing across clinical and decentralized settings. It is the most direct comparator to a portable molecular diagnostic device company like Biopix-T.
• BioFire Diagnostics (bioMérieux): BioFire's FilmArray and SpotFire platforms are widely deployed, easy-to-use molecular diagnostic systems for DNA/RNA panels in clinical and point-of-care settings, closely mirroring Biopix-T's product concept and use cases.
• Cue Health: Cue Health built a connected, portable molecular diagnostic device plus consumer/professional software for DNA/RNA testing. It is a direct peer in product form factor (portable device + software) and target use cases, though at a much later commercial stage.
• Visby Medical: Visby Medical develops a palm-sized, single-use PCR device for infectious disease DNA/RNA testing without separate instruments. It targets the same decentralized, rapid-molecular niche as Biopix-T.
• GenMark Diagnostics (now part of Roche): GenMark's ePlex system delivers rapid, sample-to-answer molecular diagnostic results for a syndromic respiratory and blood culture ID menu, directly comparable to a portable molecular diagnostic device with multiplex DNA/RNA panels.

Broad incumbents

• Roche (cobas Liat): Roche's cobas Liat is a compact, rapid PCR system for DNA/RNA testing in CLIA-waived and point-of-care environments. As part of a much larger diagnostics franchise, it competes for the same clinical workflows Biopix-T targets.
• Abbott (ID NOW): Abbott's ID NOW platform is a benchtop rapid molecular diagnostic device used at the point of care. As part of Abbott's broad diagnostics portfolio, it is a benchmark for clinical performance, menu, and pricing pressure on smaller entrants.
• QuidelOrtho: QuidelOrtho offers the Savanna rapid molecular platform and a broad diagnostic menu including DNA/RNA assays. As a large incumbent with established distribution, it competes for the same hospital and POC molecular testing budgets.

Emerging players

• Molbio Diagnostics: Molbio's Truelab and Truenat systems are portable, battery-operated real-time PCR platforms widely used in resource-limited and decentralized settings. Comparable form factor and assay menu to Biopix-T's portable molecular concept.
• T2 Biosystems: T2 Biosystems develops direct-from-sample molecular diagnostic instruments (e.g., T2Candida, T2Bacteria) that bypass culture for rapid DNA-based detection. It is comparable as a smaller, specialized molecular diagnostic instrument company.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/Biopix_T

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopix-T